Possibia

743938

Last Update Posted: 2015-10-12

Recruiting has ended

All Genders

accepted

18 Years +

141 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib

Eligibility

Relevant conditions:

Non Small Cell Lung Cancer

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

No valid contacts available

Data sourced from ClinicalTrials.gov